These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26715117)

  • 1. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of CYP2A6 polymorphism on adjuvant S-1 chemotherapy outcomes in patients with curatively resected gastric cancer].
    Hu FK; Shen J; Gao SW
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1915-1918. PubMed ID: 29996281
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.
    Kong SY; Lim HS; Nam BH; Kook MC; Kim YW; Ryu KW; Lee JH; Choi IJ; Lee JS; Park YI; Kim NK; Park SR
    Pharmacogenomics; 2009 Jul; 10(7):1147-55. PubMed ID: 19604090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
    Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
    Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
    Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
    Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
    Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
    Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
    Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
    Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
    Yang L; Zou S; Shu C; Song Y; Sun YK; Zhang W; Zhou A; Yuan X; Yang Y; Hu S
    Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):255-262. PubMed ID: 28811232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
    Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
    Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer.
    Shi C; Yang B; Chen Q; Yang J; Fan N
    Oncology; 2011; 80(5-6):289-95. PubMed ID: 21778768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
    Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
    Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
    Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of S-1 adjuvant chemotherapy benefit in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis.
    Nakamura K; Hatakeyama K; Furukawa K; Fujiya K; Kamiya S; Hikage M; Tanizawa Y; Bando E; Ohshima K; Urakami K; Machida N; Yasui H; Yamaguchi K; Terashima M
    Gastric Cancer; 2020 Jul; 23(4):648-658. PubMed ID: 32185558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.